Axsome Therapeutics (AXSM) Retained Earnings (2015 - 2026)

Axsome Therapeutics has disclosed Retained Earnings across 12 years of filings, most recently posting -$1.4 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.4 billion, down 15.93% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 15.93% YoY), and the FY2025 annual result was -$1.3 billion, down 16.31% from the prior year.
• Retained Earnings came in at -$1.4 billion for Q1 2026 at Axsome Therapeutics, down from -$1.3 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$448.8 million in Q1 2022 to a low of -$1.4 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$903.9 million (2024), against an average of -$902.9 million.
• Across the five-year window, Retained Earnings sank 48.78% in 2024 and slipped 15.93% in 2026, its largest moves.
• Axsome Therapeutics' Retained Earnings stood at -$596.3 million in 2022, then tumbled by 40.12% to -$835.6 million in 2023, then plunged by 34.37% to -$1.1 billion in 2024, then decreased by 16.31% to -$1.3 billion in 2025, then retreated by 4.94% to -$1.4 billion in 2026.
• The last three Retained Earnings figures came in at -$1.4 billion (Q1 2026), -$1.3 billion (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.